Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27656995 | 0.86 | KDM4E (0.30) | KDM4E | |
| SCHEMBL4097938 | 0.81 | LMNA (0.39) | KDM4ELMNACYP3A4GABRA1TSHR | |
| SCHEMBL28535571 | 0.77 | KDM4E (0.34) | KDM4ELMNAKMT2A | |
| SCHEMBL7998472 | 0.77 | KDM4E (0.34) | KDM4EKMT2A | |
| SCHEMBL1782970 | 0.77 | — | — | |
| SCHEMBL1903347 | 0.77 | TSHR (0.33) | TSHRKMT2A | |
| SCHEMBL1684239 | 0.76 | KDM4E (0.37) | KDM4ELMNACYP3A4GABRA1TSHR | |
| SCHEMBL28404636 | 0.76 | KDM4E (0.33) | KDM4E | |
| SCHEMBL795676 | 0.75 | CA1 (0.36) | KDM4ETSHRKMT2AALDH1A1 | |
| SCHEMBL18591289 | 0.75 | CA1 (0.36) | KDM4ETSHRKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014037886-A1 | PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2014-03-13 | — | — | WO | claimed |
| CN-101068798-B | Salts and crystals of 1-cyclopropylmethyl-4- [2- (3,3,5, 5-tetramethylcyclohexyl) phenyl ] piperazine | EISAI R&D MAN CO LTD | 2010-05-12 | — | — | CN | claimed |
| CN-101068798-A | Salts and crystals of 1-cyclopropylmethyl-4- [ 2- (3,3,5, 5-tetramethylcyclohexyl) phenyl ] piperazine | EISAI R&D MAN CO LTD (JP) | 2007-11-07 | — | — | CN | claimed |
| CN-1089086-C | Luminandide medicine | MILLS RANDELL L (US) | 2002-08-14 | — | — | CN | claimed |
| CN-119367311-A | Doxazosin mesylate sustained release tablet and preparation method thereof | 南京易亨制药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-117777116-A | Preparation method of high-purity doxazosin mesylate F crystal form | 合肥立方制药股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-110283162-B | Epidermal growth factor receptor inhibitor and application thereof | 辽宁大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-113750063-A | Solid preparation of piperazine isethionate cetirizine and preparation method thereof | 江苏食品药品职业技术学院 | 2021-12-07 | — | — | CN | disclosed |
| CN-108558865-B | Derivative taking pyrido [2,3-d ] pyrimidine structure as mother nucleus, and preparation method and application thereof | 辽宁大学 | 2021-06-01 | — | — | CN | disclosed |
| US-10695449-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10426770-B2 | Process for the preparation of Lurasidone hydrochloride | Jubilant Generics Limited (IN) | 2019-10-01 | — | — | US | disclosed |
| CN-110283162-A | A kind of novel epidermal growth factor receptor inhibitor and its application | 辽宁大学 | 2019-09-27 | — | — | CN | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| CN-1362954-A | Sulfamidohydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2002-08-07 | — | — | CN | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| CN-1301149-A | Lofuridine tablets | UPJOHN CO (US) | 2001-06-27 | — | — | CN | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
| CN-87107548-A | Strengthen the compositions of transdermal flux | — | 1988-05-11 | — | — | CN | disclosed |
| CN-87104918-A | The drug-containing fibers of controllable release | — | 1988-01-27 | — | — | CN | disclosed |
| EP-0034284-B1 | PIPERAZINE DERIVATIVE, PROCESSES FOR PREPARING THE SAME AND THERAPEUTIC COMPOSITIONS CONTAINING IT | Tanabe Seiyaku Co., Ltd. (JP) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695449-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | KDM4E 230/4885LMNA 3906/4885CYP3A4 2708/4885 |
| US-10426770-B2 | Process for the preparation of Lurasidone hydrochloride | FFAR3, REN, LSS | KDM4E 3399/4885LMNA 3313/4885CYP3A4 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.